We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Ipilimumab

News List

NICE approves first immunotherapy combination for advanced bowel cancer patients with rare MSI-H/dMMR mutation firstwordpharma
June 15, 2021
Bristol Myers Squibb (BMS) today announced that the National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Document (FAD) recommending the combination of nivolumab plus ipilimumab for advanced colorectal (bowel) cancer.
FDA Approves Nivolumab plus Ipilimumab, Chemotherapy for Metastatic NSCLC americanpharmaceuticalreview
June 03, 2020
The Food and Drug Administration (FDA) approved the combination of nivolumab (OPDIVO, Bristol-Myers Squibb) plus ipilimumab (YERVOY, Bristol-Myers Squibb) ...
FDA Grants Accelerated Approval to Nivolumab, Ipilimumab Combination americanpharmaceuticalreview
March 18, 2020
The Food and Drug Administration (FDA) granted accelerated approval to the combination of nivolumab and ipilimumab (OPDIVO and YERVOY, Bristol-Myers Squibb Co.) ...
Nivolumab cuts relapse by one third compared to Ipilimumab europeanpharmaceuticalreview
September 12, 2017
Alternative immunotherapy drug nivolumab is more effective than current standard of care in treating advanced melanoma after surgical removal of disease.